Search
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].
Products: METILDOPA MK 250 MG TABLETASMoexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalIt works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Epinastine
go.drugbank.com/drugs/DB00751ApprovedIt has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Chloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedThe safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments.
Sodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalSodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine.
Mixtures: FERTOMCIDINA U, FERTOMCIDINA UGanirelix
go.drugbank.com/drugs/DB06785ApprovedInvestigational[A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]
Prademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalPhase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.